Key result
Rivaroxaban treatment in patients with nonvalvular atrial fibrillation resulted in 2.0 thromboembolic events and 1.7 major bleeding events per 100 patient-years.
Why the study?
Does rivaroxaban prevent thromboembolic events and minimize bleeding in real-life patients with nonvalvular atrial fibrillation?
Observational
No
Does rivaroxaban prevent thromboembolic events and minimize bleeding in real-life patients with nonvalvular atrial fibrillation?
Rivaroxaban demonstrated low discontinuation rates and acceptable safety and efficacy profiles in real-world patients with nonvalvular AF managed in a hematology unit.
Supports acceptable real-world safety and efficacy of rivaroxaban in nonvalvular AF; leaves open need for randomized confirmation.
AIM: To assess the clinical profile and thromboembolic and bleeding events in patients with nonvalvular atrial fibrillation (AF) who were attended in a hematology unit. METHODS: Retrospective study of AF patients that started treatment with rivaroxaban between February 2012 and June 2016 in a hematology unit from a tertiary hospital in Spain. RESULTS: -VASc 3.7 ± 1.5) were included. After a mean follow-up of 16.5 ± 12.7 months, rivaroxaban was discontinued in only 2.4% of patients. During the follow-up, seven (2.0 events/100 patient-years) patients had a thromboembolic event and six patients (1.7 events/100 patient-years) a major bleeding. CONCLUSION: Rivaroxaban was effective and safe among AF patients treated in a hematology unit, with very low discontinuation rates.
No takes yet. Share an insight, caveat, or question.
Sebastián et al. (2018) conducted an observational in Nonvalvular atrial fibrillation. Rivaroxaban was evaluated on Thromboembolic events. Rivaroxaban treatment in patients with nonvalvular atrial fibrillation resulted in 2.0 thromboembolic events and 1.7 major bleeding events per 100 patient-years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: